Number of de novo acute myeloid leukemia case subjects aged 16 to 69 on United Kingdom Medical Research Council trial, not in analysis of adult case-control study, with cytogenetic abnormality by NQO1
| Cytogenetics3-150 . | Wild type . | Heterozygote + Homozygote . | ||
|---|---|---|---|---|
| No. . | % . | No. . | % . | |
| Total | 118 | 54.4 | 99 | 45.6 |
| t(15;17) | 48 | 50.0 | 48 | 50.0 |
| t(8;21) | 26 | 65.0 | 14 | 35.0 |
| Inv(16) | 11 | 34.4 | 21 | 65.6 |
| 5q−/7q− | 33 | 67.4 | 16 | 32.6 |
| Cytogenetics3-150 . | Wild type . | Heterozygote + Homozygote . | ||
|---|---|---|---|---|
| No. . | % . | No. . | % . | |
| Total | 118 | 54.4 | 99 | 45.6 |
| t(15;17) | 48 | 50.0 | 48 | 50.0 |
| t(8;21) | 26 | 65.0 | 14 | 35.0 |
| Inv(16) | 11 | 34.4 | 21 | 65.6 |
| 5q−/7q− | 33 | 67.4 | 16 | 32.6 |
Cytogenetic abnormality was assessed by Pearson's χ2 = 11.04; P = .01.
NQO1 indicates NAD(P)H:quinone oxidoreductase 1.
Cases were classified hierarchically as follows: t(15;17); t(8;21); inv(16); and 5q−/7q− (which includes −5/5q−/−7/7q−).